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South Africa has 5.6 million people living with HIV, 
including approximately 280 000 children1 who suffer 
disproportionate morbidity and double the mortality of 
their HIV-uninfected counterparts.2,3 Past progress in 
reducing national child mortality has been reversed 
by paediatric HIV, with under-5 mortality rates (U5MR) 
increasing from 56 to 67 deaths per 1 000 live births 
between 1990 and 2008.4 Much of the increase in the 
U5MR can be accounted for by deaths in young HIV-
infected infants, many of whom progress rapidly to AIDS 
and death from opportunistic infections, without early 
initiation of antiretroviral therapy (ART).5,6 
South Africa introduced the prevention of mother-to-
child transmission (PMTCT) and ART programmes 
nationwide in 2001 and 2004, respectively. The national 
PMTCT guidelines at the time of this study (2007) 
recommended HAART for pregnant women with a CD4 
count <200 cells/µl or zidovudine (AZT) from 28 weeks’ 
gestation plus intrapartum single-dose nevirapine 
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Background and design. HIV is a major contributor to childhood morbidity and mortality in South Africa. We 
describe HIV prevalence, disease profile, outcome and missed opportunities for early intervention in a cohort of 
HIV-infected children admitted to Chris Hani Baragwanath Hospital’s general paediatric wards between 1 October 
2007  and 31 December 2007. 
Results. Of 1 510 admissions, 446 (29.5%) were HIV infected. Many children (238, 54.1%) were newly diagnosed 
in hospital and most had advanced HIV disease (405, 92%). The principal admission diagnoses were pneumonia 
(165, 37.5%), gastro-enteritis (97, 22%), sepsis (86, 19.5%) and tuberculosis (92, 21%). Of children identified 
as HIV infected before admission, 128/202 (63.4%) were not accessing antiretroviral treatment (ART), although 
121/128 (94.5%) met ART eligibility criteria. Of 364 ART-naïve eligible children, only 15 (4.1%) were commenced 
on ART as inpatients. Problems with PMTCT implementation in infants under 6 months (N=166) included lack of 
maternal antenatal HIV testing (51, 30.7%); poor uptake of maternal/infant nevirapine prophylaxis (60, 36.2%); 
limited use of co-trimoxazole (CTX) prophylaxis (44/147, 29.9%); and delayed infant HIV polymerase chain 
reaction testing (98/147, 87.5%). Of infants known to be HIV infected prior to hospitalisation, 37/51 (73%) had not 
initiated ART. The in-hospital case fatality rate (CFR) among HIV-infected children was triple that of the combined 
HIV-uninfected, exposed and unknown group (12% v. 3.6%). Infants <12 months of age accounted for 73.6% of 
all HIV-related deaths (CFR 17.1%).
Conclusions. HIV remains highly prevalent and contributes to significant in-hospital mortality. Missed 
opportunities for PMTCT, HIV diagnosis and ART initiation are frequent. Interventions to optimise paediatric HIV 
outcomes should target maternal HIV diagnosis, early infant diagnosis, uptake of CTX prophylaxis and prompt 
initiation of ART, especially among infants. Hospitalised ART-eligible children should be prioritised for inpatient 
initiation of ART.
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(sdNVP) at CD4 counts >200 cells/µl. All infants were 
scheduled to receive sdNVP at delivery. The policy for 
early infant diagnosis (EID) at the time recommended 
HIV polymerase chain reaction (PCR) testing at 6 weeks 
of life, and for breastfed babies a repeat HIV PCR test 
6 weeks after complete cessation of breastfeeding. 
ART initiation was recommended for any child with 
clinically advanced disease (WHO HIV stage 3 or 4) or 
immunological compromise (CD4 <20% in children less 
than 18 months of age and CD4 <15% in children over 
18 months).7 Despite national implementation of these 
programmes, coverage and uptake of PMTCT, EID and 
paediatric ART programmes were highly variable between 
provinces.8 More recently, improved coverage of these 
interventions has been achieved; however, many infants 
miss entry points for the PMTCT programme and routine 
HIV testing. Others may be identified but are lost from 
the system or become ill before ART is initiated.9 These 
children typically present to hospital with advanced HIV 
disease and consequently have high mortality rates.10,11 
Chris Hani Baragwanath hospital (CHBH) is South 
Africa’s largest public sector hospital, delivering care 
to the burgeoning urban and low-income population of 
Soweto, Johannesburg. Paediatric HIV prevalence at 
CHBH (described in two previous studies prior to the 
implementation of PMTCT programmes) rose from 3% to 
19%12 to 29%13 between 1992 and 1996. Over the same 
period the proportion of paediatric in-hospital mortality 
accounted for by HIV increased dramatically from 
6.7% to 46.1%.12 Similar trends in HIV prevalence and 
HIV-related mortality in other South African hospitals 
have been reported from a national data collection 
programme, Child PIP.10,11 We report on paediatric HIV 
period prevalence, disease profile and outcome of 
children admitted to CHBH in the last quarter of 2007, 
several years after introduction of national PMTCT and 
paediatric HIV management programmes. In addition 
we describe missed opportunities for HIV prevention, 
diagnosis and medical intervention among this cohort of 
HIV-infected children. 
METHODS
Ethics. The study was approved by University of the 
Witwatersrand Human Research Ethics Committee 
(reference No. M080202). 
Study site. The study was undertaken at CHBH, Soweto, 
Johannesburg, in the Gauteng province of South Africa. 
This 2 964-bed referral hospital is the only public hospital 
serving approximately 3.5 million Sowetans and accepts 
referrals from local primary health care clinics, regional 
hospitals in Gauteng and neighbouring provinces of South 
Africa. In 2010, the estimated HIV prevalence in Gauteng 
province was 10.5%.14 The province’s health sector, 
although challenged by high TB and HIV prevalence, is 
relatively well resourced and staffed when compared with 
other areas of South Africa. The hospital and all referring 
institutions follow national PMTCT and HIV management 
guidelines.  A dedicated paediatric HIV clinic on the hospital 
premises (Harriet Shezi clinic) provides outpatient services 
to more than 3 500 HIV-infected children and the Perinatal 
HIV Research Unit (PHRU) provides PMTCT support in the 
Soweto area. 
Study design and sampling. A cross-sectional 
retrospective review of all children (from birth to 14 years of 
age) hospitalised in the general paediatric wards between 
1 October 2007 and 31 December 2007 was performed. 
Newborns with reactive HIV PCR test results during their 
stay in the neonatal unit were not included in this study, 
unless they were subsequently admitted to the general 
paediatric wards during the 3-month study period. Patient 
admission numbers and profile over this 3-month period 
did not differ significantly from the preceding three-quarters 
of 2007. Two populations were of interest (Fig. 1). Firstly, 
admission register lists of all hospitalised children were 
used to determine HIV status (collected from laboratory and/
or hospital records) and calculate HIV period prevalence. 
Secondly, individual patient records for children identified 
as HIV infected were reviewed. Monthly paediatric mortality 
reports were used to calculate in-hospital mortality. Self-
reported data on PMTCT coverage were analysed only for 
HIV-infected infants less than 6 months of age, to minimise 
information recall bias. For analysis of missed opportunities 
in provision of co-trimoxazole (CTX) prophylaxis and uptake 
of EID, infants <6 weeks were excluded.
Determination of HIV status. All HIV tests were performed 
by the accredited National Health Laboratory Service 
(NHLS). A reactive HIV-DNA PCR test confirmed HIV-
infected status in children under 18 months. A reactive HIV 
enzyme-linked immunosorbent assay (ELISA) confirmed 
HIV-infected status in children older than 18 months of 
age. Mothers’ self-reported HIV status (as documented in 
hospital records) was used. Four definitions were used: 
HIV uninfected refers to the infant or child being confirmed 
HIV uninfected; HIV infected refers to the infant or child 
being confirmed HIV infected; if the mother’s status was 
reportedly HIV infected and her infant had no HIV PCR 
result, the infant’s status was classified as HIV exposed. 
If maternal HIV status was unknown or uninfected and the 
child had no HIV test result in laboratory or folder records, 
the status was classified as HIV unknown. 
Case definitions and reference classifications. In cases 
where laboratory confirmation was not obtained, a working 
diagnosis was based on clinical suspicion and the World 
Health Organization (WHO) published case definitions15 for 
the following conditions:  Pneumocystis jiroveci pneumonia 
(PCP),16,17 pulmonary tuberculosis (pTB), cytomegalovirus 
(CMV) pneumonitis or disseminated disease, septicaemia, 
meningitis and urinary tract infection. HIV disease severity 
was assessed using the WHO clinical staging system 
for children15 and nutritional status using the WHO 2006 
growth standards18 for calculation of z-scores in children 
under 60 months of age. Calculation of ART eligibility was 
based on the South African national guidelines (2005)7 at 
the time of the study, using immunological (CD4% <20% 
under 18 months of age; CD4% <15% above 18 months 
of age) and clinical criteria (WHO stage 3 and 4 disease) 
only. The WHO and the South African Department of Health 
published extensively revised guidelines for child ART 
initiation in 2010. 
Statistical analysis. Data were analysed in SAS 
version 9.1 (SAS Institute Inc., Cary, NC, USA). Crude 
HIV period prevalence was calculated from ward records 
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as total HIV-infected admissions/total admissions. Case 
fatality rates in the HIV-infected and combined HIV-
uninfected, HIV-unknown and HIV-exposed groups were 
calculated from total number of deaths/total number of 
admissions for each group. For the PMTCT sub-analysis, 
frequency calculations were performed for maternal HIV 
status, sdNVP exposure, CTX prophylaxis and place 
of birth. The uptake of PMTCT interventions was then 
compared by maternal HIV status grouping using the 




Of 1 510 children admitted during the 3-month study 
period, 446 (29.5%) were HIV infected, 780 (51.7%) 
were HIV uninfected, 57 (3.8%) were HIV exposed and 
227 (15%) were of unknown HIV status (Fig. 1). For the 
446 children identified as HIV infected, 440 (98.7%) 
individual patient records were located. 
HIV-INFECTED CHILDREN: PROFILE OF STUDY POPULATION
Table I outlines the demographic and disease profile of the 
440 HIV-infected children. Almost 93% had advanced HIV 
disease (WHO stage 3 or 4) and 55.3% of children <5 years 
of age had severe malnutrition. Across all age groups, 
225/320 children (70.3%) had severe immune suppression.
REASON FOR HOSPITALISATION
Infectious disease was the principal reason for 
hospitalisation (Table I). Lower respiratory tract 
infections (including presumed PCP and presumed 
Cytomegalovirus pneumonitis) accounted for the 
majority of admissions, with the highest prevalence 
among infants. One hundred and ten children (25%) had 
a confirmed bacterial, viral or fungal infection during 
their hospital admission. Streptococcus pneumoniae 
and CMV were the most common bacterial and viral 
pathogens isolated. 
MISSED OPPORTUNITIES
Prevention of mother-to-child transmission of HIV 
Self-reported maternal HIV status and sdNVP exposure 
were analysed in HIV-infected infants under the age of 
6 months (n=166). Uptake of CTX prophylaxis and EID 
were analysed only for infants >6 weeks of age (n=147) 
so as to be consistent with programme guidelines. Fig. 
2 highlights the multiple levels of missed opportunities 
for PMTCT implementation in infants (<6 months of age) 
whose mothers reported their status as HIV infected versus 
HIV uninfected versus HIV unknown. Lack of maternal 
antenatal HIV testing was documented among 51/166 
(30.7%) mothers. There was poor uptake of maternal/
infant NVP prophylaxis (60/166, 36.2%). Usage of CTX 
prophylaxis was limited (44/147, 29.9%) and in most cases 
infant HIV PCR testing was delayed or lacking (98/147, 
87.5%). There was no association between place of birth 
(CHBH versus clinic/other hospital/home) and access 
to NVP or CTX (p=0.1288 and p=0.5818, respectively). 
Of the 147 HIV-infected infants 6 weeks - <6 months of 
age, 51 (34.7%) were known to be HIV infected while the 
remainder, 96 (65.3%), were newly diagnosed (i.e. had not 
previously had HIV PCR testing) at the time of hospital 
admission. Sixty-seven (45.6%) of the 147 infants received 
no PMTCT interventions at all. Only 20/147 (13.6%) infants 
received all recommended interventions, i.e. NVP and CTX 
and EID. Table I reflects additional missed opportunities for 
the provision of CTX prophylaxis among other categories of 
the study population. 
HIV diagnosis and antiretroviral therapy (ART) eligibility and uptake
Most children, 238/440 (54.1%), were newly diagnosed 
at the time of hospitalisation at CHBH. Newly diagnosed 
children were younger than those already known to be 
HIV infected (median 6 v. 12 months of age) (p=0.001). 
Children known to be infected and already on ART had 
a median treatment duration of 2 months and were 
significantly older than ART-naïve children (median 
age 38 v. 7 months) (p<0.0001). Of children known to 
be infected but not on ART (128/202, 63.4%), nearly 
all (121/128, 94.5%) were eligible for ART based on 
advanced disease stage. Of 364 ART-naïve eligible 
children, only 15 (4.1%) were commenced on ART as 
inpatients (Fig. 1). Table II compares eligibility for ART 
with actual ART uptake among children who died. 
OUTCOME OF HOSPITALISATION
Median duration of hospital stay was 7 days (interquartile 
range (IQR) 4 - 10.) Fifty-three children died (Table I) 
with a median duration of stay before death of 4 days 
(IQR 2 - 7.8). Only 13 children (3.0%) were admitted to 
an ICU or underwent mechanical ventilation in the high-
care area of the acute admissions ward. Ten of these 13 
children (76.9%) survived to hospital discharge. 
Fifty-eight per cent of all paediatric deaths (53/91) 
occurred among the HIV-infected group. The overall 
case fatality rate in the HIV-infected children was 53/440 
(12.0% (95% confidence interval (CI) 9.2 - 15.5%)). In 
contrast, the case fatality rate in the HIV-uninfected, 
HIV-exposed and HIV-unknown group over the study 
period was 38/1 064 (3.6% (95% CI 2.5 - 4.9%)). The 
highest case fatality rate by age group was in infants 
aged less than 12 months (Table I). The most prevalent 
causes of death included pneumonia/suspected PCP 
(18/53, 34%), TB (14/53, 26.3%) and gastro-enteritis 
(5/53, 9.4%). The inpatient mortality rate did not differ 
significantly between children receiving ART at the 
time of hospitalisation (7.9%, 6/76) versus ART-naïve 
children (13.6%, 47/345) (p=0.17, odds ratio 0.54).
DISCUSSION
HIV PREVALENCE
This paper reports the first published data on paediatric HIV 
prevalence, disease profile and outcome at CHBH subsequent 
to widespread implementation of PMTCT and paediatric HIV 
management programmes. The HIV period prevalence of 
29.5% was almost identical to that found in 1996. However, 
the true HIV prevalence remains unquantified, since both 
cohorts had large numbers of untested children. Several 
years after national roll-out of PMTCT and ART programmes, 
there is therefore little evidence of a decreasing impact of 
paediatric HIV at CHBH. Possible explanations for this could 
include increasing antenatal HIV prevalence in Gauteng 
province (15.5 - 29.8% between 1996 and 2009)19 with more 
vertical infections; failure of sdNVP PMTCT regimens; the 
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possibility of an even higher (undocumented) peak paediatric 
HIV prevalence reached between 1996 and 2007; poor 
PMTCT coverage; improved survival rates (particularly in 
older HIV-infected children on ART); and the establishment 
of a dedicated paediatric HIV clinic at CHBH (pooling children 
with complicated HIV disease).
MISSED OPPORTUNITIES
Prevention of mother-to-child transmission of HIV 
A major limitation of the chosen study design is possible 
maternal recall bias regarding PMTCT interventions. 
In addition, reported maternal HIV status could not be 
verified in all cases. Healthcare workers’ documentation 
of PMTCT interventions was poor. In order to decrease 
missed opportunities among HIV-exposed infants, 
all PMTCT interventions should be clearly explained 
to caregivers and documented in all patient records, 
especially the infants’ Road to Health Card (RTHC). 
This is the most important linkage and communication 
tool for paediatric healthcare providers, especially when 
children access care at multiple facilities.
Uptake of PMTCT interventions was poor, with almost 
half of infants under 6 months of age receiving no 
PMTCT interventions at all. Of particular concern was 
the large proportion of mothers who reported their status 
as HIV uninfected (15.1%) or HIV unknown/untested 
(30.7%). There are several possible explanations for 
the 15.1% of mothers who reported their status as 
HIV uninfected: a negative test in early pregnancy 
with subsequent seroconversion before delivery 
(3% reported seroconversion of pregnant women);20 
postnatal HIV infection with breastfeeding transmission; 
or fear of stigmatisation after disclosure of HIV status. 
Antenatal identification of HIV-infected pregnant women 
is the gateway to a successful PMTCT programme, 
since all other interventions rely on this key step. Opt-
out antenatal HIV testing, and repeat HIV testing late in 
pregnancy, during labour and at immunisation services, 
would maximise identification of HIV-infected mothers. 
In addition, clear recording of maternal HIV status on 
the infant’s RTHC would increase awareness of HIV 
exposure and hopefully prompt prescription of CTX and 
uptake of infant HIV PCR testing. This would allow for 
earlier infant diagnosis and rapid ART initiation, resulting 
in improved infant outcomes. 
The poor uptake rates reported for sdNVP and CTX 
prophylaxis in this study are alarming. Possible factors 
contributing to this problem include mothers who test 
Fig. 1. Determination of HIV prevalence and study population and ART uptake among 440 HIV-infected children. 
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at a clinic and then deliver in hospital; ‘cryptic’ written 
communication between health facilities about patients’ 
HIV status in an attempt to maintain confidentiality; 
women’s reluctance to disclose HIV status due to 
stigma; and health care workers’ reluctance to offer HIV 
testing or to enquire about HIV status. Failure to provide 
CTX prophylaxis represents a major missed opportunity 
to prevent early mortality from PCP, as demonstrated in 
this cohort with 15% of deaths ascribed to PCP. Since 





≤11 months 228 (51.8%)
12 - 35 months  85 (19.3%)
36 - 59 months  29 (6.6%)
≥5 years  98 (22.3%)
Timing of HIV diagnosis
Newly diagnosed 238 (54.1%)
Known HIV-infected 202 (45.9%)
WHO HIV stage 
I    3 (0.7%)
II   29 (6.6%)
III  188 (42.7%)
IV  220 (50%)
Median (IQR) weight-for-age z-score (WAZ)* (n=342)
≤11 months (n=228) -3.53 (-4.59 - -2.44)
12 - 35 months (n=85) -2.69 (-3.60 - -1.43)
36 - 59 months (n=29) -1.89 (-3.03 - -1.41)
No. 0 - 59 months with WAZ -3 - -2 (%) 56 (16.4)
No. 0 - 59 months with WAZ <-3 (%) 189 (55.3)
Median (IQR) CD4 percentage by age group† (n=320)
≤11 months (n=155) 18.6 (12.8 - 28)
12 - 35 months (n=57) 16.2 (9.6 - 23)
36 - 59 months (n=23) 9.1 (6.3 - 15.3)
≥5 years (n=85) 8.0 (4.5 - 14.7)
Median (IQR) CD4 absolute count (cells/µl) by age group† (N=320)
≤11 months (n=155) 700 (361 - 1294)
12 - 35 months (n=57) 565 (422 - 909)
36 - 59 months (n=23) 414 (197 - 863)
≥5 years (n=85) 171 (45 - 379)
Severe immunosuppression (all ages)‡ 225/320, 70.3.%
No. (%) of children receiving CTX prophylaxis
All HIV-infected infants <12 months of age 73/228 (32%)  
Known to be HIV-infected and not yet on ART 86/127 (67.7%)
Known to be HIV-infected and on ART <12 months 53/55 (96.4%)
Reason for hospitalisation
Pneumonia  165 (37.5%)
Gastro-enteritis  97 (22%)
Tuberculosis (including pTB + extrapulmonary TB)  92 (21%)
Sepsis          86 (19.5%)
(including septicaemia (n=48), meningitis (n=23), and urinary tract infection (n=15) 
Outcome of hospitalisation
Discharged alive 319 (72.5%)
Died 53 (12%)
Transferred to a step-down hospital facility 68 (15.5%)
Deaths by age group (case fatality rate§, 95% CI) by age group (n=53)
≤11 months 39 (17.1%, 12.5 - 22.6)
12 -35 months  4 (4.7%, 1.3 - 11.6)
36 - 59 months  2 (6.9%, 0.8 - 22.8)
≥5 years  8 (8.2%, 3.6 - 15.5)
* Calculation of WAZ scores was only done for children 0 - 59 months of age (n=342).
† CD4-positive T-cell counts and percentages were analysed in a subgroup of the study population who had had CD4 testing at any point 1 month before, during or after 
hospitalisation (n=320/440).
‡ Proportion of children with severe immunosuppression was defined using WHO (2007) criteria11 as follows: <11 months of age, CD4 <25%; 12 - 35 months, CD4 <20%; 
36 - 59 months, CD4 <15%; >5 years, CD4 <200 or <15%.
§Case fatality rate was calculated as total number of deaths per age group/total number of admissions per age group. 
TABLE I. DISEASE PROFILE OF HIV-INFECTED CHILDREN (N=440)
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Age categories
No. (%) with immunological  
criteria qualifying for ART*
No. (%) with clinically advanced 
disease (stage 3 or 4) qualifying  
for ART
No. (%) of eligible children 


























*CD4 percentage <20% for children <18 months old, CD4 <15% for children >18 months old. 
†The denominators differ from the overall group denominators because only a proportion of the 53 HIV-infected children who died had recent CD4 percentage results 
available. 
TABLE II. ELIGIBILITY FOR ART VERSUS ART ACCESS IN 53 HIV-INFECTED CHILDREN WHO DIED
Fig. 2. Missed opportunities for PMTCT implementation, CTX prophylaxis, EID and ART initiation in infants (<6 months).
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increased complexity) in PMTCT regimens. However, 
these changes will be not be effective unless universal 
uptake of PMTCT, CTX prophylaxis and early infant 
diagnosis is achieved. High loss to follow-up of HIV-
exposed infants remains a major problem in the PMTCT 
programme, both at CHBH and at a national level as 
reported by previous studies.21,22 
HIV diagnosis and antiretroviral therapy eligibility and uptake
Despite calls for universal testing, 15% of children 
admitted to CHBH had no documentation of HIV 
exposure status or HIV testing. In a subgroup (3.8%) 
noted to be HIV exposed and symptomatic (requiring 
hospitalisation), HIV PCR testing was not performed. 
Although usually recommended at 4 - 6 weeks of age, 
immediate HIV PCR testing should be performed in 
symptomatic HIV-exposed infants regardless of age 
so as to expedite ART initiation.23 Maternal HIV status, 
PMTCT interventions and results of HIV PCR testing 
should be routinely enquired about at every infant’s 
health care visit. Similarly, any child who presents with 
malnutrition must be screened for HIV, as reflected in this 
cohort, where 54.1% of children were newly diagnosed 
in hospital despite a background of malnutrition (in 72%) 
and previous hospitalisations. However, rapid HIV tests 
(used for screening or to establish HIV exposure status 
in infants) have high false-negative rates, especially 
among young infants.24 
Despite growing awareness of the benefits of paediatric 
ART at the time, ART coverage of these hospitalised 
children was low (83% of eligible children were not 
accessing ART). The short treatment duration and older 
age of children on ART at CHBH highlights the fact that 
few children and even fewer infants had the benefit of 
early ART initiation. To ensure timeous and equitable 
access for children, ART must be initiated and monitored 
at entry levels of the health care system (primary health 
care clinics).  Furthermore, hospitalised, symptomatic 
HIV-infected children should be fast-tracked for 
inpatient ART initiation. This measure should be strongly 
considered for every ART-eligible hospitalised child, and 
especially for infants ≤12 months of age, who are at 
highest risk of disease progression and death.23  In our 
study setting (a hospital with an established paediatric 
ART service), only 4.1% of ART-naïve, ART-eligible 
children had treatment commenced as an inpatient, 
despite weekly ward visits by clinicians from the onsite 
HIV clinic. In addition, none of those commenced on 
ART as inpatients were infants, despite this being the 
age category with the highest case fatality rate. We 
postulate that multiple hurdles to inpatient ART initiation 
exist, such as parental illness or death, complex social 
circumstances, advanced HIV disease and clinician 
inexperience with or reluctance to commence HAART. 
Despite these obstacles, clinicians need to be more 
aggressive in identifying and treating ART-eligible 
infants and children during ward admission. 
OUTCOME OF HOSPITALISATION
Infectious diseases such as diarrhoea, TB and PCP – 
which are preventable by immunisation, prophylaxis or 
early ART initiation – accounted for all of the deaths. Dual 
or multiple concurrent infections are well recognised 
among HIV-infected children with pneumonia. There 
were no documented cases in this cohort, but this 
may simply reflect the lack of aggressive screening for 
multiple respiratory pathogens. CMV was demonstrated 
on postmortem specimens from several patients. It 
was difficult to distinguish CMV infection from disease, 
additional laboratory testing was limited and ganciclovir 
treatment was not readily accessible at CHBH at the 
time of the study. The contribution of CMV disease to 
the burden of pneumonia and deaths in this cohort is 
therefore uncertain.
During the study, only 3% of HIV-infected children were 
admitted to ICU/high care; however, they demonstrated 
a 76.9% survival rate. Data on ICU candidate selection 
policies, duration of stay, incidence of complications 
and long-term morbidity and mortality compared with 
that of HIV-negative children admitted to ICU were not 
available. With expanding ART access and improved 
HIV outcomes, institutional policies for the admission of 
HIV-infected children to paediatric ICU facilities in South 
Africa should be reviewed.
AT CHBH from 1992 to 1996 the proportion of paediatric 
in-hospital mortality accounted for by HIV increased 
from 6.7% to 46.1% and in 2007 (this study) to 58%. 
This figure shows striking concordance with the 2008 
South African statistics from the Countdown to 2015 
report, which attributed 57% of under-5 mortality to 
HIV/AIDS (current HIV-attributable mortality is 46%).25 
Despite implementation of PMTCT and paediatric ART 
programmes, HIV prevalence and in-hospital case 
fatality rates (among HIV-infected children under 5 
years of age) have remained static between 1996 and 
2007. Over the same period, however, mortality among 
uninfected children has declined. HIV-infected children 
at CHBH are at a 3-fold increased risk of death compared 
with HIV-uninfected, HIV-exposed and HIV-unknown 
children. Hospitalised HIV-infected infants under 12 
months of age at CHBH are a particularly vulnerable 
group with a high case fatality rate (17.1%), and should 
be prioritised for early ART initiation. 
ART status at the time of hospitalisation did not 
significantly impact on inpatient mortality; however, the 
median duration of ART in the treatment group was only 
2 months, reducing the likelihood of treatment survival 
benefit. Early hospitalisations after initiation of ART 
are a well-documented phenomenon,26 but no immune 
reconstitution inflammatory syndrome (IRIS) or ART 
adverse event-related admissions were documented 
in this cohort. It is possible that these conditions were 
unrecognised and thus under-reported owing to lack of 
experience of hospital staff at that time.
This study has several limitations that may impair its 
generalisability: a retrospective study design; small 
sample size; a short study period; and lack of an HIV-
uninfected comparison group. The large percentage 
of children (15%) with unknown HIV status also limits 
the accuracy of the HIV prevalence data. Missed 
opportunities among HIV-exposed, status unknown 
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infants were also not captured. However, the data provide 
a ‘snap-shot’ of HIV impact at a large referral hospital 
and may reflect commonly encountered challenges 
to paediatric HIV care provision. Experiences after 
introduction of PMTCT and ART at CHBH may provide 
insights for other institutions struggling to implement 
best practice guidelines for paediatric HIV care. 
CONCLUSION
HIV remains highly prevalent and contributes to 
significant in-hospital mortality at CHBH. Multiple 
missed opportunities for PMTCT, HIV diagnosis and 
ART initiation were identified, demonstrating the need to 
monitor and assist with HIV guideline implementation at 
service delivery level. Interventions to optimise paediatric 
HIV outcomes should target maternal HIV diagnosis, 
early infant diagnosis, uptake of CTX prophylaxis and 
prompt initiation of ART, especially among infants. 
Hospitalised ART-eligible children should be prioritised 
for inpatient initiation of ART. Ongoing surveillance of 
HIV prevalence, disease profile and mortality at CHBH 
and other hospitals may be used to identify programmatic 
problems, plan service improvement interventions and 
measure progress towards the millennium goal of a two-
thirds reduction in U5MR by 2015.27 
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